9 Other operating income and expenses
|
millions of CHF |
|
2024 |
|
2023 |
|
|
Remeasurement of indemnification assets |
|
0.4 |
|
– |
|
|
Government assistance |
|
0.0 |
|
0.3 |
|
|
Rental income from sub-leases |
|
0.6 |
|
0.9 |
|
|
Gain from sale of property, plant and equipment |
|
0.8 |
|
0.0 |
|
|
Operating currency exchange gains, net |
|
0.3 |
|
0.7 |
|
|
Proceeds received for the sale of the former subsidiary medmix Poland |
|
– |
|
2.0 |
|
|
Change in impairments and provisions against former subsidiary medmix Poland |
|
– |
|
2.2 |
|
|
Miscellaneous other operating income |
|
0.3 |
|
1.0 |
|
|
Total other operating income |
|
2.4 |
|
7.0 |
|
|
|
|
|
|
|
|
|
Restructuring expenses |
|
–1.6 |
|
–0.8 |
|
|
Impairments on tangible and intangible assets |
|
–5.2 |
|
–3.0 |
|
|
Cost for mergers and acquisitions |
|
–0.6 |
|
–0.1 |
|
|
Miscellaneous other operating expenses |
|
–0.1 |
|
–0.0 |
|
|
Total other operating expenses |
|
–7.4 |
|
–3.9 |
|
|
|
|
|
|
|
|
|
Total other operating income / (expenses), net |
|
–5.0 |
|
3.1 |
|
Other operating income includes income from remeasurement of indemnification assets, litigation cases, government grants and incentives and recharges to third parties not qualifying as revenues from customers and other income.
Further details regarding the remeasurement of indemnification assets are disclosed in note 18.
As part of the Growth & Efficiency program, the group recognized restructuring costs of CHF 1.6 million (2023: CHF 0.8 million), mainly associated with a production facility in Germany.
As part of the Growth & Efficiency program, the group recorded impairments of production machines and facilities, mainly in Germany, and other intangible assets, mainly related to research and development projects, totaling CHF 5.2 million (2023: CHF 3.0 million). For more details on the impaired asset category, refer to note 12, note 13 and note 14.
The functional allocation of the total restructuring expenses and impairments is as follows: cost of goods sold CHF 4.0 million (2023: CHF 2.6 million), selling and administrative expenses CHF 1.4 million (2023: CHF 0.7 million) and research and development expenses CHF 1.3 million (2023: CHF 0.5 million).
In 2023, the group received CHF 2.0 million from the sale of the former subsidiary medmix Poland to a third party, resulting in a profit recognized in other operating income and a cash flow in the amount of CHF 2.0 million. The group also recognized other operating income from the change of impairments and provisions against the former subsidiary medmix Poland in the amount of CHF 2.2 million.